1,638
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway

, , , , , ORCID Icon & show all
Pages 2091-2108 | Received 10 Aug 2021, Accepted 01 Jun 2022, Published online: 13 Jun 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mingxia Song, Jiantao Wen, Yi Hua, Yangnv Zhu, Qishan Xia, Qiaoyue Guo, Yiqin Luo, Xianqing Deng & Yushan Huang. (2023) Synthesis and anticancer properties of celastrol derivatives involved in the inhibition of VEGF. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now

Articles from other publishers (3)

Shining Xiao, Yu Zhang, Zihao Liu, Anan Li, Weilai Tong, Xu Xiong, Jiangbo Nie, Nanshan Zhong, Guoqing Zhu, Jiaming Liu & Zhili Liu. (2023) Alpinetin inhibits neuroinflammation and neuronal apoptosis via targeting the JAK2/STAT3 signaling pathway in spinal cord injury. CNS Neuroscience & Therapeutics 29:4, pages 1094-1108.
Crossref
Jingjing Wang, Shuyu Feng, Qian Zhang, Huan Qin, Chunxiu Xu, Xuefei Fu, Lin Yan, Yaqin Zhao & Kai Yao. (2023) Roles of Histone Acetyltransferases and Deacetylases in the Retinal Development and Diseases. Molecular Neurobiology 60:4, pages 2330-2354.
Crossref
Xuefei Fu, Shuyu Feng, Huan Qin, Lin Yan, Caiyan Zheng & Kai Yao. (2023) Microglia: The breakthrough to treat neovascularization and repair blood-retinal barrier in retinopathy. Frontiers in Molecular Neuroscience 16.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.